David Benfer - Stereotaxis Independent Director
STXS Stock | USD 2.50 0.01 0.40% |
Director
Mr. David W. Benfer is Independent Director of Stereotaxis, Inc., He has served as the chairman of The Benfer Group LLC, which provides advisory services to healthcare providers and suppliers, since 2010. From 1999 to 2009, Mr. Benfer served as president and chief executive officer of Saint Raphael Healthcare System and the Hospital of Saint Raphael, New Haven, Connecticut. Prior to that, he was the president and chief executive officer of the ProvenaSaint JosephMorris Health Network in Joliet, Illinois from 1992 to 1999. Mr. Benfer served as senior vice president for Hospital and Urban Affairs for the Henry Ford Health System in Detroit and chief executive officer of the Henry Ford Hospital from 1985 to 1992. He served as the chairman of the American College of Healthcare Executives from 1998 to 1999 and on its board of governors from 1992 to 2000. Mr. Benfer was named a Fellow of ACHE in 1981 and served on the board of the Catholic Health Association from 2003 until 2008. Mr. Benfer also serves as a director of a private financial institution and chairman of the board of a private healthcare service company. He earned his M.B.A. from Xavier University and his B.S.B.A. from Wittenburg University. Mr. Benfers extensive experience in the healthcare industry and in hospital management provides the Company with useful industry information related to technology acquisition, governance, and risk and liability issues. since 2005.
Age | 70 |
Tenure | 19 years |
Professional Marks | MBA |
Address | 710 North Tucker Boulevard, Saint Louis, MO, United States, 63101 |
Phone | 314 678 6100 |
Web | https://www.stereotaxis.com |
Stereotaxis Management Efficiency
The company has return on total asset (ROA) of (0.2864) % which means that it has lost $0.2864 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7693) %, meaning that it created substantial loss on money invested by shareholders. Stereotaxis' management efficiency ratios could be used to measure how well Stereotaxis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to gain to -0.72 in 2024. At this time, Stereotaxis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 38.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 4.7 M in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Harald Arnet | National Research Corp | N/A | |
Frank Gordon | HealthStream | 55 | |
John Nunnelly | National Research Corp | 65 | |
Savita Acharya | National Research Corp | 41 | |
Evelyn Dilsaver | HealthEquity | 62 | |
Adrian Dillon | HealthEquity | 63 | |
Brita Eilertsen | National Research Corp | 53 | |
Jeffrey McLaren | HealthStream | 51 | |
Frank Medici | HealthEquity | 53 | |
Kjersti Kanne | National Research Corp | N/A | |
JoAnn Martin | National Research Corp | 63 | |
Donald Berwick | National Research Corp | 71 | |
Frank Corvino | HealthEquity | 68 | |
Martin Harris | HealthStream | 61 | |
Thompson Dent | HealthStream | 68 | |
Deborah Tate | HealthStream | 61 | |
Barbara Mowry | National Research Corp | 70 | |
Manu Rana | HealthEquity | 45 | |
Michael Shmerling | HealthStream | 62 | |
Gayle Wellborn | HealthEquity | 56 | |
Debra McCowan | HealthEquity | 46 |
Management Performance
Return On Equity | -0.77 | ||||
Return On Asset | -0.29 |
Stereotaxis Leadership Team
Elected by the shareholders, the Stereotaxis' board of directors comprises two types of representatives: Stereotaxis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stereotaxis. The board's role is to monitor Stereotaxis' management team and ensure that shareholders' interests are well served. Stereotaxis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stereotaxis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Duane DeSisto, Director | ||
Ross Levin, Director | ||
Paul Brathwaite, Vice President - Research & Development | ||
Laura Garth, General Secretary | ||
Arun Menawat, Director | ||
CAIA CFA, CEO Chairman | ||
Joseph Keegan, Independent Director | ||
John Platt, Director Software | ||
Joseph Kiani, Director | ||
Fred Middleton, Independent Director | ||
Keith Galloway, Vice Operations | ||
Guy Judkowski, Equity Manager | ||
David Fischel, Director | ||
Brian Kidd, RD Devel | ||
Euan Thomson, Independent Director | ||
Eric Prystowsky, Independent Director | ||
Karen Duros, Sr. VP, General Counsel and Secretary | ||
Frank Cheng, Sr. VP of Marketing and Bus. Devel. | ||
Susan Lanigan, Executive Vice President General Counsel | ||
David Giffin, VP of HR | ||
Martin Stammer, CFO and Principal Accounting Officer | ||
Nathan Kastelein, RD Concepts | ||
Robert Messey, Independent Director | ||
William Mills, Chairman of the Board, CEO | ||
Nathan Fischel, Director | ||
David Benfer, Independent Director | ||
Kimberly Peery, CFO Secretary |
Stereotaxis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stereotaxis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.77 | ||||
Return On Asset | -0.29 | ||||
Profit Margin | (0.77) % | ||||
Operating Margin | (1.16) % | ||||
Current Valuation | 195.74 M | ||||
Shares Outstanding | 82.13 M | ||||
Shares Owned By Insiders | 15.87 % | ||||
Shares Owned By Institutions | 47.49 % | ||||
Number Of Shares Shorted | 925.39 K | ||||
Price To Earning | 21.61 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stereotaxis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stereotaxis' short interest history, or implied volatility extrapolated from Stereotaxis options trading.
Currently Active Assets on Macroaxis
When determining whether Stereotaxis is a strong investment it is important to analyze Stereotaxis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Stereotaxis' future performance. For an informed investment choice regarding Stereotaxis Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stereotaxis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Stereotaxis Stock please use our How to Invest in Stereotaxis guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Stereotaxis Stock analysis
When running Stereotaxis' price analysis, check to measure Stereotaxis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stereotaxis is operating at the current time. Most of Stereotaxis' value examination focuses on studying past and present price action to predict the probability of Stereotaxis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stereotaxis' price. Additionally, you may evaluate how the addition of Stereotaxis to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Stereotaxis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stereotaxis. If investors know Stereotaxis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stereotaxis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 0.332 | Quarterly Revenue Growth (0.38) | Return On Assets (0.29) | Return On Equity (0.77) |
The market value of Stereotaxis is measured differently than its book value, which is the value of Stereotaxis that is recorded on the company's balance sheet. Investors also form their own opinion of Stereotaxis' value that differs from its market value or its book value, called intrinsic value, which is Stereotaxis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stereotaxis' market value can be influenced by many factors that don't directly affect Stereotaxis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stereotaxis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stereotaxis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stereotaxis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.